Introduction
Two previous surveys attempted to assess The following information was requested: (1) whether or not female patients were routinely screened for C trachomatis, and if so which test or tests were used; (2) which antibiotic was normally used to treat women with chlamydia, including dosage and duration of treatment; (3) whether or not a test of cure (TOC) was routinely performed after women had completed treatment, and ifso which test or tests were used and when they were carried out.
Results
Responses were obtained from 207 clinics (94.5%). One hundred and ninety seven clinics, 95 2% of those replying, routinely screened for chlamydia in female patients. Screening was not done in 10 clinics (4.8%). Two of these clinics reported no chlamydial diagnostic service and one reported a very limited service. Table 1 shows the methods used for screening. There is considerable variation in the treatment prescribed for chlamydial infection of the cervix. In their most recent guidelines both the World Health Organisation (WHO)3 and the Centers for Disease Control (CDC)4 recommended the same antibiotic regimens. First-line therapy is doxycycline 100 mg twice a day or tetracycline 500 mg four times a day for seven days. Alternative therapies are erythromycin 500 mg four times a day for seven days or sulfisoxazole 500 mg four times a day for ten days (or equivalent doses of other sulphonamides).
The results of clinical studies indicate that lower doses are adequate. Tetracycline 1 g/day, erythromycin 1 g/day, Deteclo 600 mg/day, and doxycycline 200 mg stat proceeding to 100 mg/day have all been shown to be effective when given for seven days. '5 From the results of this survey, even considering minocycline to be equivalent to doxycycline and oxytetracycline to be equivalent to tetracycline, only 97 (47%) of the 207 clinics who supplied information on treatment used an antibiotic regimen compatible with the advice of the WHO and CDC. Of these clinics 176 (85%) prescribed antibiotics in larger doses and/or for longer durations than those known to be effective in published reports.
There is equally wide variation in the costs of the therapies used. The cheapest regime costs the National Health Service 17p (oxytetracycline 0.5 g/ day for seven days) and the most expensive costs £20.90p (doxycycline 400 mg/day for ten days). Of the treatments recommended by the WHO and CDC the cheapest costs 68p (oxytetracycline 2 g/day for seven days) and the most expensive costs £7-32p (doxycycline 200 mg/day for seven days). The prices quoted are for the generic drugs alone and make no allowance for the cost of packaging and Value Added Tax, or for locally-negotiated pricing agreements.
Eighty six percent of clinics routinely perform a TOC but both the WHO and CDC advise that this is unnecessary.34 This recommendation is supported by the following laboratory and clinical evidence: (a) naturally occurring resistance of C trachomatis to the tetracyclines and erythromycin has never been described,9 (b) in the largest series of women followed after treatment for cervical chlamydial infection, C trachomatis was reisolated in only 10%. Reinfection and not treatment failure was the probable explanation in all cases.'0 As many clinics perform more than one TOC and/or utilise more than one microbiological method, there would be considerable savings in time, money and discomfort to the patient if this advice was followed.
Apparent treatment failure may result from noncompliance or reinfection through further unprotected intercourse. If the clinician believes a TOC to be necessary it is inadvisable to repeat microbiological tests immediately after finishing treatment. Antigen detection tests such as EIA and DFA may give misleading positive results in this situation due to persisting antigens from non-viable chlamydia." Culture may fail to detect chlamydiae due to the suppressive action of antibiotics." In this survey 16% of clinics incorporated an immediate TOC in their follow-up.
